Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Acquired by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC grew its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 23.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 47,500 shares of the biopharmaceutical company’s stock after purchasing an additional 9,000 shares during the quarter. Celldex Therapeutics makes up approximately 1.3% of AlphaCentric Advisors LLC’s holdings, making the stock its 19th biggest holding. AlphaCentric Advisors LLC owned about 0.07% of Celldex Therapeutics worth $1,758,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Values First Advisors Inc. grew its position in shares of Celldex Therapeutics by 8.3% during the 2nd quarter. Values First Advisors Inc. now owns 21,319 shares of the biopharmaceutical company’s stock valued at $789,000 after buying an additional 1,627 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Celldex Therapeutics by 53.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 139,162 shares of the biopharmaceutical company’s stock valued at $5,150,000 after buying an additional 48,231 shares during the last quarter. Mirador Capital Partners LP grew its position in shares of Celldex Therapeutics by 7.3% during the 2nd quarter. Mirador Capital Partners LP now owns 112,379 shares of the biopharmaceutical company’s stock valued at $4,159,000 after buying an additional 7,620 shares during the last quarter. DNB Asset Management AS grew its position in shares of Celldex Therapeutics by 47.2% during the 2nd quarter. DNB Asset Management AS now owns 7,872 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 2,523 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Celldex Therapeutics during the 1st quarter valued at about $824,000.

Celldex Therapeutics Stock Performance

Shares of NASDAQ:CLDX traded up $0.53 during trading on Monday, reaching $37.70. The company had a trading volume of 426,266 shares, compared to its average volume of 777,705. The firm’s fifty day moving average is $36.53 and its 200 day moving average is $38.72. The firm has a market capitalization of $2.48 billion, a PE ratio of -13.04 and a beta of 1.58. Celldex Therapeutics, Inc. has a twelve month low of $22.11 and a twelve month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The company had revenue of $2.50 million during the quarter, compared to analyst estimates of $1.13 million. Equities analysts predict that Celldex Therapeutics, Inc. will post -2.5 earnings per share for the current fiscal year.

Insider Activity at Celldex Therapeutics

In related news, VP Elizabeth Crowley sold 30,000 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $34.87, for a total transaction of $1,046,100.00. Following the completion of the sale, the vice president now directly owns 9,074 shares of the company’s stock, valued at $316,410.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, VP Richard M. Wright sold 46,844 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $33.72, for a total value of $1,579,579.68. Following the completion of the sale, the vice president now owns 20,833 shares in the company, valued at approximately $702,488.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Elizabeth Crowley sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $34.87, for a total transaction of $1,046,100.00. Following the completion of the sale, the vice president now owns 9,074 shares of the company’s stock, valued at approximately $316,410.38. The disclosure for this sale can be found here. Insiders sold a total of 266,332 shares of company stock valued at $9,155,821 over the last ninety days. Insiders own 3.80% of the company’s stock.

Analysts Set New Price Targets

CLDX has been the subject of a number of recent research reports. Wolfe Research initiated coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price objective for the company. Stifel Nicolaus initiated coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, July 30th. Finally, Wells Fargo & Company upped their target price on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $63.83.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.